# Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events

> **NCT01924325** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 10000 (estimated)

## Conditions studied

- Ischemic Stroke
- TIA

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Clopidogrel
- **DRUG:** Aspirin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01924325
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2015-12
- **Final completion:** 2016-07
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2013-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01924325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01924325, "Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01924325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*